Kristina Lindemann, Head of the Gynecological Oncology Center at Oslo University Hospital, shared a post on LinkedIn:
“Congratulation to our post doctor Carlos Casas Arozamena to this paper on longitudinal ctDNA sampling in patients with endometrial cancer.
Choosing the best method for detection is still a challenge: We here provide important insights by the direct comparison of a tumor-agnostic NGS panel with a tumor-informed ddPCR approach.
The cfDNA-NGS panel identified a broad spectrum of alterations, including relapse-specific mutations indicative of clonal evolution, but showed (as expected) lower sensitivity for low-frequency variants compared with ddPCR.
Thanks for this great collaboration!
Therese Sørlie, Laura Muinelo Romay, Eva Colás, University of Oslo, Oslo University Hospital.”
Title: Longitudinal circulating tumor DNA profiling in patients with advanced endometrial cancer using an off-the-shelf targeted NGS panel
Authors: Carlos Casas-Arozamena, Karin Teien Lande, Eva Diaz, Ana Vilar, Juan Cueva, Efigenia Arias, Victoria Sampayo, Alicia Abalo, Nerea González, Eva Colás, Antonio Gil-Moreno, Miguel Abal, Gema Moreno-Bueno, Therese Sørlie, Kristina Lindemann, Laura Muinelo-Romay.
Other articles featuring Kristina Lindemann on OncoDaily.